Adaptive Biotechnologies (ADPT) CCO Susan Bobulsky Receives Award

What Happened
Susan Bobulsky, Chief Commercial Officer (MRD) of Adaptive Biotechnologies (ADPT), received two equity awards on 2026-03-04: 59,375 shares and 62,500 shares (transaction code A — grant/award). Both awards were reported with an acquisition price of $0.00, for a total of 121,875 shares granted. The Form 4 was filed on 2026-03-06.

Key Details

• Transaction date(s): 2026-03-04 (filed 2026-03-06). Filing appears timely under the two-business-day Form 4 rule.
• Awards: 59,375 shares (A) and 62,500 shares (A); price reported $0.00 for each grant.
• Total shares awarded: 121,875.
• Shares owned after transaction: Not specified in the filing.
• Notable footnotes: None disclosed on the filing; no 10b5-1, tax withholding, or cashless exercise indicated.
• Filing timeliness: Not marked late.

Context
Transaction code A indicates these are grants/awards (typically equity compensation such as restricted stock or RSUs being issued), not open-market purchases or sales. Such awards are part of executive compensation and do not by themselves signal a buy/sell decision in the market.